Mobile

A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with multip...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-007015-32

A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with multiple sclerosis, followed by a 1-year open-label treatment phase

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that rivastigmine patch (target patch size 10 cm²) has superior efficacy compared to placebo on a change from baseline of the total recall score of the selective reminding test (SRT) of the Brief Repeatable Battery of Neuropsychological Tests (BRB-N) in cognitive impaired MS patients after 16 weeks of treatment.

Critère d'inclusion

  • cognitive impairment in Multiple Sclerosis

Liens